Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10

“…A significantly greater reduction in total cholesterol was observed in SUSTAIN 3 with semaglutide than with exenatide ER in the background MET ? SU subgroup but not in the background MET subgroup, driven both by a greater reduction with semaglutide 1.0 mg and a lower reduction with Table 4 Adverse events leading to premature treatment discontinuation in the safety analysis set The proportion of subjects who prematurely discontinued treatment because of adverse events was mostly consistent between background OAD subgroups, but the proportion was generally higher with semaglutide than with comparators, as observed across the SUSTAIN programme [8][9][10][11][12][13][14][15][16][17]. Across the four SUSTAIN trials analysed here, the event rate for severe or BG-confirmed symptomatic hypoglycaemia and minor hypoglycaemia reported with semaglutide was either comparable to or lower than the rate with active comparators (liraglutide, exenatide ER, sitagliptin or insulin glargine).…”

“…Semaglutide is a GLP-1 analogue, with 94% amino acid homology to native GLP-1. The efficacy and safety of once-weekly subcutaneous (s.c.) administration of semaglutide has been established in the global phase 3 clinical trial programme SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes), which has included a broad range of subjects with T2D with or without background OADs or insulin [8][9][10][11][12][13][14][15][16][17].…”

“…The number and type of background OAD therapies in subjects varied across the SUSTAIN trials and included MET (which is considered the backbone of T2D treatment and recommended as first-line therapy by most treatment guidelines) as a monotherapy or in combination with SU, one of the most common second-line therapies [3][4][5]7]. Subjects in the SUSTAIN trials remained on stable therapy, including prior background treatment, unless rescue criteria were met [8][9][10][11][12][13][14][15][16][17].…”

Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 diabetes

“…The combined search of the PubMed, Embase, and the Cochrane Library databases identified 973 citations, of which 13 articles with 7350 participants met all inclusion criteria. After removal of duplicates, the title and abstracts of search results were screened for relevance.…”

“…Characteristics of eligible studies are presented in Table S1 from which five studies compared the simultaneous combination of SGLT2is and DPP4is versus SGLT2is in drug‐naive or metformin failure patients, while the other eight studies compared the addition of incretin‐based agents with a placebo as add‐on therapy in patients inadequately controlled with SGLT2is. Overall, there were four combined types of SGLT2is/DPP4is (Canagliflozin/Teneligliptin, Dapagliflozin/Saxagliptin, Empagliflozin/Linagliptin, and Ertugliflozin/Sitagliptin), and three types of SGLT2is/GLP‐1RAs (Dapagliflozin/Exenatide, SGLT2is/Dulaglutide, and SGLT2is/Semaglutide).…”